What is included in patient education about emtricitabine/tenofovir for preexposure prophylaxis (PrEP) against HIV infection?

Updated: Oct 08, 2019
  • Author: Alejandro Delgado, MD; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print


When prescribing emtricitabine/tenofovir for PrEP, healthcare providers must: [3]

  • Prescribe emtricitabine/tenofovir as part of a comprehensive prevention strategy because this drug combination is not always effective in preventing the acquisition of HIV-1 infection.

  • Counsel all uninfected individuals to strictly adhere to the recommended emtricitabine/tenofovir dosing schedule because the effectiveness of Truvada in reducing the risk of acquiring HIV-1 was strongly correlated with adherence as demonstrated by measurable drug levels in clinical trials.

  • Confirm a negative HIV-1 test immediately prior to initiating emtricitabine/tenofovir for a PrEP indication. If clinical symptoms consistent with acute viral infection are present and recent (< 1 month) exposures are suspected, delay starting PrEP for at least 1 month and reconfirm HIV-1 status or use a test approved by the FDA as an aid in the diagnosis of HIV-1 infection, including acute or primary HIV-1 infection.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!